English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Methods 664 ARV-naive HIV-1-infected subjects were randomized 1:1:1:1 to lopinavir/ritonavir (LPV/r) once-daily (QD) SGC, twice-daily (BID) SGC, QD tablet, BID tablet for eight weeks. All subjects received tenofovir (TDF) + emtricitabine (FTC) QD. At week 8, subjects taking LPV/r SGC were switched to the tablet formulation while maintaining their QD or BID dosing schedule. All subjects will be followed for up to 96 weeks. Metabolic evaluations at baseline (BL) and week 48 are presented.

journal of the international aids society

Metabolic evaluation of Study M05-730: LPV/r tablets QD vs. BID, co-administered with tenofovir DF + emtricitabine in ARV-naïve HIV-1 infected subjects